UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Nicotine receptor partial agonists for smoking cessation

Cochrane database of systematic reviews, 2016-05, Vol.2016 (5), p.CD006103

2016

Volltextzugriff (PDF)

Lessons from a failed γ-secretase Alzheimer trial

Cell, 2014-11, Vol.159 (4), p.721-726

De Strooper, Bart

2014

Volltextzugriff (PDF)

Pharmacotherapies for sleep disturbances in dementia

Cochrane database of systematic reviews, 2020-11, Vol.11 (11), p.CD009178

2020

Volltextzugriff (PDF)

Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials

Biological psychiatry (1969), 2016-01, Vol.79 (2), p.136-148

2016

Volltextzugriff (PDF)

Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas

Journal of clinical oncology, 2014-01, Vol.32 (1), p.44-50

2014

Volltextzugriff (PDF)

A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

The New England journal of medicine, 2013-07, Vol.369 (4), p.341-350

2013

Volltextzugriff (PDF)

Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial

Journal of clinical oncology, 2016-04, Vol.34 (12), p.1368-1375

2016

Volltextzugriff (PDF)

Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention

Neurology, 2014-09, Vol.83 (11), p.958-966

2014

Volltextzugriff (PDF)

Zavegepant Intranasal Spray for Migraines

The Annals of pharmacotherapy, 2024-08, Vol.58 (8), p.827-833

2024

Volltextzugriff (PDF)

Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study

The lancet oncology, 2015-04, Vol.16 (4), p.395-405

2015

Volltextzugriff (PDF)

Suvorexant for the treatment of primary insomnia: a systematic review and meta-analysis

Sleep medicine reviews, 2017-10, Vol.35, p.1-7

2017

Volltextzugriff (PDF)

Preventive Effects of Suvorexant on Delirium: A Randomized Placebo-Controlled Trial

The journal of clinical psychiatry, 2017-09, Vol.78 (8), p.e970-e979

2017

Volltextzugriff (PDF)

Learning by Failing: Ideas and Concepts to Tackle γ-Secretases in Alzheimer's Disease and Beyond

Annual review of pharmacology and toxicology, 2015-01, Vol.55 (1), p.419-437

2015

Volltextzugriff (PDF)

Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial

The Lancet (British edition), 2008-12, Vol.372 (9656), p.2115-2123

2008

Volltextzugriff (PDF)

Long-term safety of zavegepant nasal spray for the acute treatment of migraine: A phase 2/3 open-label study

Cephalalgia, 2024-08, Vol.44 (8), p.3331024241259456

2024

Volltextzugriff (PDF)

Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study

Clinical cancer research, 2012-11, Vol.18 (21), p.6058-6064

2012

Volltextzugriff (PDF)

Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations

Clinical cancer research, 2012-09, Vol.18 (17), p.4775-4784

2012

Volltextzugriff (PDF)

Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men

Sleep (New York, N.Y.), 2013-02, Vol.36 (2), p.259-267

2013

Volltextzugriff (PDF)

Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma

Annals of oncology, 2016-10, Vol.27 (10), p.1855-1860

2016

Volltextzugriff (PDF)

Non-GABA sleep medications, suvorexant as risk factors for falls: Case-control and case-crossover study

PloS one, 2020-09, Vol.15 (9), p.e0238723

2020

Volltextzugriff (PDF)

Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors

Clinical cancer research, 2012-09, Vol.18 (17), p.4764-4774

2012

Volltextzugriff (PDF)

Suvorexant for the prevention of delirium: A meta-analysis

Medicine (Baltimore), 2020-07, Vol.99 (30), p.e21043

2020

Volltextzugriff (PDF)

Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

International journal of clinical practice (Esher), 2014-12, Vol.68 (12), p.1429-1441

Citrome, L.

2014

Volltextzugriff (PDF)

1 – 25 von 424

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(358)
Mit Volltextzugriff
(270)

Publikationsform

Artikel
(424)

Sprache

6 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(364)
Science & Technology
(331)
Life Sciences & Biomedicine
(323)
Azepines - Adverse Effects
(270)
Male
(253)
Female
(227)
Azepines - Therapeutic Use
(183)
Adult
(163)
Middle Aged
(150)
Aged
(119)
Pharmacology & Pharmacy
(119)
Azepines - Administration & Dosage
(116)
Azepines - Pharmacology
(116)
Animals
(105)
Biological And Medical Sciences
(104)
Medical Sciences
(97)
Double-Blind Method
(82)
Pharmacology. Drug Treatments
(69)
Treatment Outcome
(62)
Neurosciences & Neurology
(51)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Nicotine receptor partial agonists for smoking cessation

Lessons from a failed γ-secretase Alzheimer trial

A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers

Pharmacotherapies for sleep disturbances in dementia

Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials

Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas

A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial

Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention

Zavegepant Intranasal Spray for Migraines

Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study

Suvorexant for the treatment of primary insomnia: a systematic review and meta-analysis

Preventive Effects of Suvorexant on Delirium: A Randomized Placebo-Controlled Trial

Learning by Failing: Ideas and Concepts to Tackle γ-Secretases in Alzheimer's Disease and Beyond

Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial

Long-term safety of zavegepant nasal spray for the acute treatment of migraine: A phase 2/3 open-label study

Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study

Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations

Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men

Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma

Non-GABA sleep medications, suvorexant as risk factors for falls: Case-control and case-crossover study

Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors

Suvorexant for the prevention of delirium: A meta-analysis

Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

Suchergebnisse filtern